FLUO Share Price Performance
SEK 32.50
-9.60 (-22.80%)
56.0% undervalued intrinsic discount
SEK 73.85
Fair Value
Price SEK 32.50
AnalystConsensusTarget SEK 73.85
Fair ValueSEK 73.85
Share Pricen/a
Narrative Update • Jun 26
FluoGuide A/S Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
FLUO Community Narratives
AN
Fair Value
·Fair Value SEK 73.85 56.0% undervalued intrinsic discount
Regulatory Alignment And Phase II Success Will Support A Wider Surgical Imaging Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Regulatory Alignment And Phase II Success Will Support A Wider Surgical Imaging Opportunity
A small biotech is trying to help surgeons see and remove cancer more accurately by making tumors light up during operations, and early trial results suggest it could work across several hard-to-treat brain and head-and-neck cancers. FDA alignment and partnerships with major surgical equipment makers could speed adoption, but the whole story hinges on more trials, approvals, and whether hospitals and insurers are willing to pay.Read more
AN
SEK 73.85
56.0% undervalued intrinsic discount
Fair Value
Profit Margin
20.95%
Future PE
90.85x
Price in 2029
SEK 61.32
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
FLUO: Strong Brain Tumor Surgery Data Will Support Future Upside
Fair Value: SEK 73.85 56.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
FluoGuide A/S Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 25, 2026
- -2.59
- 100.00%
- -17,810.92%
- 63.3%
About FLUO
- Founded
- 2018
- Employees
- 7
- CEO
- WebsiteView website
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer. The company was incorporated in 2018 and is based in Copenhagen, Denmark.
